Literature DB >> 7886716

Human leukocyte antigen in patients with moyamoya disease.

M Aoyagi1, K Ogami, Y Matsushima, M Shikata, M Yamamoto, K Yamamoto.   

Abstract

BACKGROUND AND
PURPOSE: Progressive stenosis or occlusion of bilateral internal carotid arteries by fibrocellular intimal thickening results in cerebral ischemia in moyamoya disease. In an attempt to elucidate the still-unknown etiologic factors in moyamoya disease, we assessed human leukocyte antigens in patients with this disease.
METHODS: We investigated 32 unrelated Japanese patients with moyamoya disease for typing of human leukocyte antigen A, B, C, and DR/DQ and compared the results with those from 178 unrelated control subjects.
RESULTS: We found a significant association of human leukocyte antigen B51 with moyamoya disease (corrected P < .05, chi 2 test). Although no significant associations were observed in DR/DQ typing, the frequency of the B51-DR4 combination was significantly higher in moyamoya patients than in control subjects (P < .002, Fisher's exact test).
CONCLUSIONS: These findings suggest that there may be a genetic predisposition for moyamoya disease and that host factors may play a role in the development of intimal thickening in early childhood.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7886716     DOI: 10.1161/01.str.26.3.415

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

1.  A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians.

Authors:  Wanyang Liu; Hirokuni Hashikata; Kayoko Inoue; Norio Matsuura; Yohei Mineharu; Hatasu Kobayashi; Ken-Ichiro Kikuta; Yasushi Takagi; Toshiaki Hitomi; Boris Krischek; Li-Ping Zou; Fang Fang; Roman Herzig; Jeong-Eun Kim; Hyun-Seung Kang; Chang-Wan Oh; David-Alexandre Tregouet; Nobuo Hashimoto; Akio Koizumi
Journal:  Environ Health Prev Med       Date:  2009-11-19       Impact factor: 3.674

2.  Association of HLA-DR and -DQ Genes with Familial Moyamoya Disease in Koreans.

Authors:  Seok Ho Hong; Kyu-Chang Wang; Seung-Ki Kim; Byung-Kyu Cho; Myoung Hee Park
Journal:  J Korean Neurosurg Soc       Date:  2009-12-31

3.  Serum alpha1-antitrypsin level and phenotype associated with familial moyamoya disease.

Authors:  Toshiyuki Amano; Satoshi Inoha; Chun-Ming Wu; Toshio Matsushima; Kiyonobu Ikezaki
Journal:  Childs Nerv Syst       Date:  2003-07-25       Impact factor: 1.475

Review 4.  Single Nucleotide Polymorphism in Patients with Moyamoya Disease.

Authors:  Young Seok Park
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

Review 5.  Moyamoya disease and syndromes: from genetics to clinical management.

Authors:  Stéphanie Guey; Elisabeth Tournier-Lasserve; Dominique Hervé; Manoelle Kossorotoff
Journal:  Appl Clin Genet       Date:  2015-02-16

6.  Identification of HLA-DRB1*04:10 allele as risk allele for Japanese moyamoya disease and its association with autoimmune thyroid disease: A case-control study.

Authors:  Ryosuke Tashiro; Kuniyasu Niizuma; Seik-Soon Khor; Katsushi Tokunaga; Miki Fujimura; Hiroyuki Sakata; Hidenori Endo; Hidetoshi Inoko; Koetsu Ogasawara; Teiji Tominaga
Journal:  PLoS One       Date:  2019-08-14       Impact factor: 3.240

7.  Association of HLA-DQA2 and HLA-B With Moyamoya Disease in the Chinese Han Population.

Authors:  Jiang Wan; Wei Ling; Zhang Zhengshan; Zuo Xianbo; Duan Lian; Wang Kai
Journal:  Neurol Genet       Date:  2021-06-02

Review 8.  The Genetic Basis of Moyamoya Disease.

Authors:  R Mertens; M Graupera; H Gerhardt; A Bersano; E Tournier-Lasserve; M A Mensah; S Mundlos; P Vajkoczy
Journal:  Transl Stroke Res       Date:  2021-09-16       Impact factor: 6.829

9.  Analysis of HLA Variants and Graves' Disease and Its Comorbidities Using a High Resolution Imputation System to Examine Electronic Medical Health Records.

Authors:  Wen-Ling Liao; Ting-Yuan Liu; Chi-Fung Cheng; Yu-Pao Chou; Tzu-Yuan Wang; Ya-Wen Chang; Shih-Yin Chen; Fuu-Jen Tsai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-07       Impact factor: 5.555

Review 10.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.